Neurokinin-1 receptors located in human retinoblastoma cell lines: Antitumor action of its antagonist, L-732,138

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 6, 2007, Pages 2775-2781

  Muñoz, Miguel ^a   Rosso, Marisa ^a   Coveñas, Rafael ^b   Montero, Ignacio ^a   González Moles, Miguel Angel ^c   Robles, María José ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PEROXIDASE; SUBSTANCE P; TETRAZOLIUM; UNCLASSIFIED DRUG; 3,5 BIS(TRIFLUOROMETHYL)BENZYL N ACETYLTRYPTOPHAN; 3,5-BIS(TRIFLUOROMETHYL)BENZYL N-ACETYLTRYPTOPHAN; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; TRYPTOPHAN;

ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL DENSITY; CELL LINE; CELL VIABILITY; CHROMATIN CONDENSATION; COLORIMETRY; CONTROLLED STUDY; COULTER COUNTER; DOSE RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINOBLASTOMA; TUMOR CELL; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; RETINA TUMOR; STEREOISOMERISM; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL COUNT; CELL PROLIFERATION; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOENZYME TECHNIQUES; PIPERIDINES; RECEPTORS, NEUROKININ-1; RETINAL NEOPLASMS; RETINOBLASTOMA; STEREOISOMERISM; SUBSTANCE P; TRYPTOPHAN; TUMOR CELLS, CULTURED;

EID: 34347273792     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1591     Document Type: Article

References (39)

1. Albert DM. Historic review of retinoblastoma. Ophthalmology. 1987;94:654-662.
2. Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 1999;36:8-18.
3. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108:128-132.
4. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer. 2005;5:91-101.
5. Bremner R, Chen D, Pacal M, Livne-Bar I, Agochiya M. The RB protein family in retinal development and retinoblastoma: new insights from new mouse models. Develop Neurosci. 2004;26:417-434.
6. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11:317-327.
7. Muñoz M, Rosso M, Pérez A, et al. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci. 2005;46:2567-2570.
8. Tarkkanen A, Tervo T, Tervo K, Eränkö L, Eränkö O, Cuello AC. Substance P immunoreactivity in normal human retina and in retinoblastoma. Ophthalmic Res. 1983;15:300-306.
9. Casini G, Dal Monte M, Fornai F, et al. Neurokinin 1 receptor expression and substance P physiological actions are developmentally regulated in the rabbit retina. Neuroscience. 2004;124:147-160.
10. Catalani E, Gangitano C, Bosco L, Casini G. Expression of the neurokinin 1 receptor in the mouse retina. Neuroscience. 2004;128:519-530.
11. Catalani E, Dal Monte M, Gangitano C, et al Expression of substance P, neurokinin 1 receptors (NK1) and neurokinin 3 receptors in the developing mouse retina and in the retina of NK1 knockout mice. Neuroscience. 2006;138:487-499.
12. von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol. 1931;72:74-87.
13. Pernow B. Substance P. Pharmacol Rev. 1983;35:85-141.
14. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med. 2001;249:27-40.
15. Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R. Antitumoral action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res. 2004;14:183-188.
16. Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E. Antitumoral action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol. 2004;142:105-112.
17. MacLeod AM, Merchant KJ, Brookfield F, et al. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J Med Chem. 1994;37:1269-1274.
18. Cascieri MA, MacLeod AM, Underwood D, et al. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem. 1994;269:6587-6591.
19. Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain. 2002;95:277-285.
20. 3 receptors regulate vascular permeability changes in the skin of mast cell-deficient mice. Int Immunopharmacol. 2003;3:1563-1568.
21. Muñoz M, Rosso M, Soult JA, Coveñas R. Antitumoral action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV, ed. Brain Cancer Therapy and Surgical Interventions. 1st ed. New York: Nova Biomedical Books; 2006:45-75.
22. Reeve JG, Bleehen NM. [D-Arg(1)-D-Phe(5),D-Trp(7,9),Leu(11)] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Com. 1994;199:1313-1319.
23. Muñoz M, Rosso M, Perez A, et al. The NK1 receptor is involved in the antitumoral action of L-733,060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides. 2005;39:427-432.
24. Coveñas R, Martín F, Salinas P, et al. An immunocytochemical mapping of methionine-enkephalin-arg(6)-gly(7)-leu(8) in the human brainstem. Neuroscience. 2004;128:843-859.
25. Schulz S, Stumm R, Röcken C, Mawrin C, Schulz S. Immunolocalization of full-length NK1 tachykinin receptors in human tumors. J Histochem Cytochem. 2006;54:1015-1020.
26. Caberlotto L, Hurd YL, Murdock P, et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci. 2003;17:1736-1746.
27. McGillis JP, Organist ML, Payan DG. Immunoaffinity purification of membrane protein constituents of the IM-9 lymphoblast receptor for substance P. Anal Biochem. 1987;164:502-513.
28. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci. 1990;594:85-94.
29. Nakata Y, Hiraoka C, Segawa T. Apparent molecular weight of the substance P binding site in rat brain. Eur J Pharmacol. 1988;152:171-174.
30. van Ginkel FW, Pascual DW. Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R. J Neuroimmunol. 1996;67:49-58.
31. Woll PJ, Rozengurt E. [D-Arg(1)-D-Phe(5), D-Trp(7,9), Leu(11)] Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA. 1988;35:1859-1863.
32. Langdon S, Sethi T, Richie A, Muir M, Smyth J, Rozengurt E. Broad-spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. 1992;52:4554-4557.
33. Seckl MJ, Higgins T, Wildmer F, Rozengurt E. [D-Arg(1), D-Trp(5,7, 9), Leu(11)] Substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. 1997;57:51-54.
34. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. Anti-tumor activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenografts. Br J Cancer. 2000;82:480-487.
35. Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest. 2003;83:731-742.
36. Sharif TR, Luo W, Houghron PJ, Sharif M. Substance K peptide induces mitogenesis by activating the mitogen-activated protein kinase signalling pathway through the substance P receptor (NK-1 subtype) in human astrocytoma. Cell Pharmacol. 1996;3:441-449.
37. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33:555-576.
38. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 1996;56:4983-4991.
39. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumor growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer. 1999;79:236-243.